Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on Equity

Inhibikase Therapeutics (IKT) Equity Average (2020 - 2025)

Inhibikase Therapeutics (IKT) has disclosed Equity Average for 6 consecutive years, with $76.5 million as the latest value for Q3 2025.

  • On a quarterly basis, Equity Average rose 3249.76% to $76.5 million in Q3 2025 year-over-year; TTM through Sep 2025 was $76.5 million, a 3249.76% increase, with the full-year FY2024 number at $52.9 million, up 230.63% from a year prior.
  • Equity Average was $76.5 million for Q3 2025 at Inhibikase Therapeutics, down from $82.9 million in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $90.3 million in Q1 2025 to a low of $2.3 million in Q3 2024.
  • A 5-year average of $33.2 million and a median of $27.3 million in 2022 define the central range for Equity Average.
  • Peak YoY movement for Equity Average: tumbled 86.76% in 2024, then skyrocketed 3249.76% in 2025.
  • Inhibikase Therapeutics' Equity Average stood at $40.8 million in 2021, then plummeted by 43.4% to $23.1 million in 2022, then crashed by 43.7% to $13.0 million in 2023, then surged by 262.89% to $47.2 million in 2024, then soared by 62.14% to $76.5 million in 2025.
  • Per Business Quant, the three most recent readings for IKT's Equity Average are $76.5 million (Q3 2025), $82.9 million (Q2 2025), and $90.3 million (Q1 2025).